HBM Holdings expands AstraZeneca biotherapeutics collaboration to next-generation drugs

HBM Holdings Limited and its indirect wholly-owned subsidiary, Harbour BioMed (Shanghai) Co., Ltd., have advanced their collaboration with AstraZeneca PLC as of November 24, 2025. This follows an amendment to their initial collaboration agreement dated March 21, 2025.

The updated scope now includes the discovery and development of next-generation biotherapeutics, such as antibody-drug conjugates (ADCs) and T cell engagers, leveraging the combined expertise of both companies. The economic terms of this expanded collaboration remain consistent with the financial framework previously established.

This announcement aims to inform shareholders and potential investors about the latest business developments within the group. The company advised shareholders and potential investors to exercise due care when dealing in its shares, as there is no guarantee that HBM Holdings or its partners will successfully develop or ultimately market the product candidates.